MedPath

The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease

Withdrawn
Conditions
Sleep Deprivation
Alzheimer Disease
Blood Brain Barrier Defect
Sleep Apnea
Interventions
Diagnostic Test: Diagnostic Test
Registration Number
NCT04096261
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

The aim of our study is the analysis of sleep phases and quality as well as the detection of respiratory pauses in subjects with cognitive disorder. To assess whether sleep quality is associated with the blood-brain barrier and Alzheimer's disease, which may be indicative of an early, non-invasively measurable change in brain activity in the early stages of Alzheimer's disease.

Detailed Description

The aim of our study is the analysis of sleep phases and quality as well as the detection of respiratory pauses in subjects with cognitive disorder. To assess whether sleep quality is associated with the blood-brain barrier and Alzheimer's disease, which may be indicative of an early, non-invasively measurable change in brain activity in the early stages of Alzheimer's disease.

Sleep quality impairment is a known risk factor for memory impairment. There is increasing evidence of a link between measurable sleep parameters, in particular a reduction of slow waves of deep sleep in cognitive deficits. Also, breathing pauses during sleep are associated with increased daytime sleepiness and cognitive impairment. This observational study is intended to establish a possible link between subjective memory disturbances and altered sleep quality or respiratory breaks during sleep. In the run-up to this study, they performed a special MRI scan of the head and a lumbar puncture (removal of nerve water) in a different context. The aim of this imaging study and the new biomarker in brain water was to investigate the function of the blood-brain barrier that occurs in Alzheimer's disease. The results of the studies on the quality of sleep should be evaluated in the context of this study in connection with the findings of the MRI examination and lumbar puncture.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Subjective cognitive declineDiagnostic TestIndividuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
Mild cognitive impairmentDiagnostic TestIndividuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
Siblings of people with Alzheimer's dementiaDiagnostic TestSiblings of people with Alzheimer's dementia recruited through public advertisement
Dementia due to Alzheimer's diseaseDiagnostic TestIndividuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
Healthy controlsDiagnostic TestHealthy controls recruited through public advertisement.
Primary Outcome Measures
NameTimeMethod
Marker of blood-brain dysfunction using MRI1 day

Dynamic T1 contrast enhanced sequence using Gadovist

Markers of blood-brain dysfunction using CSF1 day

Platelet-derived growth factor receptor-β in CSF

Sleep quality measurement2 day

Polysomnography

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Charité Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath